---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000149"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:46:25.508307+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera

## Summary
- Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.
- Raises FY2025 adj diluted EPS guidance to $3.00-$3.15 from $2.90-$3.10; reaffirms revenue $61-64B.
- Reached landmark agreement with U.S. government on drug pricing; sues Novo Nordisk for tortious interference over Metsera acquisition.
- Inclacumab fails Phase 3 THRIVE-131 in sickle cell disease; $1.35B IPR&D charge for 3SBio deal.
- Expects ~$7.2B net cost savings by 2027; no share repurchases planned; $7.3B dividends paid YTD.

## SEC filing metadata
- accession: 0000078003-25-000149
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/0000078003-25-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000149
- JSON: https://secwatch.observer/filing/0000078003-25-000149.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.